Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

New England Journal of Medicine

Volumn 339, Issue 19, 1998, Pages 1349-1357

  Tonkin, A ^a   Alyward, P ^a   Colquhoun, D ^a   Glasziou, P ^a   Harris, P ^a   Hunt, D ^a   Keech, A ^a   MacMahon, S ^a   Magnus, P ^a   Newel, D ^a   Nestel, P ^a   Sharpe, N ^a   Shaw, J ^a   Simes, R J ^a   Thompson, P ^a   Thompson, A ^a   West, M ^a   White, H ^a   Simes, S ^a   Hague, W ^a   Caleo, S ^a   Hall, J ^a   Martin, A ^a   Mulray, S ^a   Barter, P ^a   Beilin, L ^a   Collins, R ^a   McNeil, J ^a   Meier, P ^a   Willimott, H ^a   Smithers, D ^a   Wallace, P ^a   Baker, J ^a   Hobbs, M ^a   Sullivan, D ^a   Anderson, N ^a   Hankey, G ^a   Watson, J ^a   Arulchelvam, M ^a   Chup, S ^a   Daly, J ^a   Hanna, J ^a   Leach, A ^a   Lee, M ^a   Loughhead, J ^a   Lundie Jenkin, H ^a   Morrison, J ^a   Netting, S ^a   Nguyen, A ^a   Pater, H ^a   Philip, R ^a   Pinna, G ^a   Rattos, D ^a   Ryerson, S ^a   Sazhin, V ^a   Walsh, R ^a   Claque, A ^a   Mackie, M ^a   Yallop, J ^a   Boss, K ^a   Shepard, M ^a   Leach, J ^a   Gandy, M ^a   Joughin, J ^a   Seabrook, J ^a   Abraham, R ^a   Allen, J ^a   Bates, F ^a   Beinart, I ^a   Breed, E ^a   Brown, D ^a   Bunyan, N ^a   Calvert, D ^a   Campbell, T ^a   Condon Paoloni, D ^a   Conway, B ^a   Coupland, L ^a   Crowe, J ^a   Cunio, N ^a   Cuthbert, B ^a   Cuthbert, N ^a   D'Arcy, S ^a   Davidson, P ^a   Dwyer, B ^a   England, J ^a   Friend, C ^a   Fulcher, G ^a   Grant, S ^a   Hellestrand, K ^a   Kava, M ^a   Kritharides, L ^a   McGill, D ^a   McKee, H ^a   McLean, A ^a   Neaverson, M ^a   Nelson, G ^a   O'Neill, M ^a   Onuma, C ^a   O'Reilly, F ^a   more..

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PRAVASTATIN; RISK;

EID: 0032487931     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199811053391902     Document Type: Article

References (23)

1. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
2. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994;308:363-6.
3. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in populations with low cholesterol concentrations. BMJ 1991;303:276-82.
4. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C-77C.
5. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-9.
6. Muldoon MF, Manuck SB, Mathews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
7. Peto R, Yusuf S, Collins R. Cholesterol lowering trial results in their epidemiological context. Circulation 1985;72:Suppl III:451. abstract.
8. Keech A. Does cholesterol lowering reduce total mortality? Postgrad Med J 1992;68:870-1.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
11. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995;76:474-9.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
14. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
15. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York: John Wiley, 1992.
16. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
17. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196-201.
18. The EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-82. [Erratum, Eur Heart J 1998;19:356-7.]
19. Théroux P, Lidón R-M. Unstable angina: pathogenesis, diagnosis, and treatment. Curr Probl Cardiol 1993;18:157-231.
20. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11.
21. Pearson TA, McBride PE, Miller NH, Smith SC. Task Force 8: organization of preventive cardiology service. J Am Coll Cardiol 1996;27:1039-47.
22. Keech A. Risk factor management in CHD patients in Asia: current status. Atherosclerosis 1998;136:Suppl:S31. abstract.
23. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996;75:334-42.